All News

Early results from a registry of patients with small renal masses support the safety of active surveillance using a standardized protocol.

Margaret S. Pearle, MD, PhD, discusses the scope of radiation exposure and how to minimize risk from it.

Two additional years of results from the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirm original findings that screening significantly reduces death from prostate cancer.

Jim C. Hu, MD, MPH, will join the UCLA urology faculty in April 2012.

Ohio state Senator Nina Turner (D-Cleveland) recently announced legislation that she says would protect men in Ohio from the risks of phosphodiesterase type-5 inhibitors used to treat erectile dysfunction.

Quest Diagnostics (Madison, NJ) recently announced the availability of a molecular blood test for identifying renal organ-transplant rejection.

Circumcision before a male's first sexual intercourse may help protect against prostate cancer, according to a recent study.

Khurshid Guru, MD, director of the Center for Robotic Surgery at Roswell Park Cancer Institute, Buffalo, NY, has been named the Dr. Robert P. Huben Professor of Urologic Oncology.

Treatment is still overused in older men with prostate cancer and a short life expectancy, say the authors of a study from Yale School of Medicine, New Haven, CT.

High percentages of radiation oncologists and medical oncologists discuss the impact of cancer treatments on fertility with their patients of childbearing age, but the frequency of these discussions varies widely by specialty, according to a recent study.

Janssen Research & Development, LLC, recently has unblinded the phase III study of the androgen biosynthesis inhibitor abiraterone acetate (ZYTIGA) plus prednisone for the treatment of asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) who have not received chemotherapy.

Urologic oncologist Steven E. Canfield, MD, has been named chief of the division of urology in the department of surgery at The University of Texas Health Science Center at Houston (UTHealth) Medical School.

The FDA recently approved the InTone device (InControl Medical, LLC, Brookfield, WI) to treat female urinary incontinence.

Male fetuses of mothers that are exposed to radiation during early pregnancy may have an increased chance of developing testicular cancer, report researchers from the University of Texas MD Anderson Cancer Center, Houston.

Men receiving testosterone supplementation who also receive the 5-alpha-reductase inhibitor dutasteride (Avodart) do not experience a significant difference in changes in muscle mass, muscle strength, or sexual function compared with men who do not receive dutasteride, according to a recent study.

The AUA has revised its best practice statement on antibiotic prophylaxis for transrectal prostate biopsy to incorporate recent Centers for Medicare & Medicaid Services approval of intramuscular administration of antimicrobials.

Urologists who gathered for the annual Joint Advocacy Conference listened politely as a member of the U.S. Preventive Services Task Force explained the thinking behind the group's recommendation against routine PSA testing, but few, if any of them seemed to have been swayed.

The gene expression analysis of urine sediment could provide a noninvasive way to analyze interstitial cystitis in some patients, according to a recent study.

Curcumin, an active component of the Indian curry spice turmeric, may help slow down tumor growth in castration-resistant prostate cancer patients on androgen deprivation therapy, report researchers from Thomas Jefferson University?s Kimmel Cancer Center, Philadelphia.

Daily use of long-acting opioids increases the risk of hypogonadism in men compared with those taking short-acting opioids, according to a recent study.

Results from three separate clinical trials further support the efficacy and tolerability of the investigational beta3-adrenoceptor agonist mirabegron for the treatment of OAB, researchers reported at the 2012 European Association of Urology annual congress in Paris.

The AUA and the American Association of Clinical Urologists have lost no time in pressing Congress for a better solution on Medicare physician reimbursement following passage of legislation to delay a 27% cut in payments for 10 months.

New data showing an increasing incidence of pediatric stone disease is stimulating more research to further describe and understand this troubling phenomenon.

Injectable long-acting testosterone undecanoate (Aveed) over 9 to 12 months is well tolerated by hypogonadal men, especially in regard to prostate safety and response to concomitant phosphodiesterase type-5 inhibitor therapy.

Results of a survey of pediatricians' practice patterns for children with vesicoureteral reflux (VUR) are worrisome in showing these primary care practitioners are retaining their patients longer before referring them to a specialist.

Radiologically proven VUR was present in 11 mothers and seven fathers as well as in 36 second-degree relatives (aunts, uncles, grandparents) and 73 third-degree relatives (65 first cousins and eight great-aunts, -uncles or -grandparents) of 259 VUR patients in an Irish study.

Results of a retrospective study investigating risk factors for the development of renal parenchymal damage in young children with primary high-grade vesicoureteral reflux (VUR) underscore the importance of early detection and treatment to prevent renal damage or its progression from ongoing VUR.